Tg Therapeutics: Bollinger Bands Narrowing, KDJ Death Cross on 15min Chart
ByAinvest
Thursday, Sep 18, 2025 12:04 pm ET1min read
TGTX--
On September 12, 2025, a 15-minute chart analysis of TGTX revealed a narrowing of Bollinger Bands, indicating a reduction in the magnitude of stock price fluctuations. Additionally, a KDJ Death Cross is projected to occur on September 18, 2025, at 12:00, which signals a shift in momentum towards the downside, potentially leading to further decreases in stock price [1].
Despite these technical signals, analysts at B. Riley Securities maintain a Buy rating for TGTX, raising the price target from $53.00 to $55.00, reflecting a 3.77% increase. The analyst responsible for this update, Mayank Mamtani, attributes the increase to recent market evaluations and strategic company developments [1].
The consensus among Wall Street analysts is also favorable, with an average target price of $42.00 and an average brokerage recommendation of "Outperform". GuruFocus estimates a GF Value for TGTX of $89.71, suggesting a potential upside of 177.48% from the current price of $32.33 [1].
However, the projected KDJ Death Cross and Bollinger Bands narrowing indicate a cautious approach for investors. While the company's pipeline and recent FDA approval for BRIUMVI for the treatment of relapsing forms of multiple sclerosis (RMS) are positive developments, the technical indicators suggest a potential downward trend in the short term.
Investors should closely monitor TGTX's stock performance and consider the implications of the upcoming KDJ Death Cross on September 18, 2025, while also keeping an eye on the company's broader strategic developments and market evaluations.
Tg Therapeutics's 15-minute chart has recently exhibited Bollinger Bands Narrowing, and a KDJ Death Cross is projected to occur on September 18, 2025, at 12:00. This signals a reduction in the magnitude of stock price fluctuations and a shift in momentum towards the downside, with the potential for further decreases in stock price.
TG Therapeutics (TGTX) has recently experienced a notable shift in its stock price dynamics, with technical indicators suggesting a potential downturn. Analysts, however, remain optimistic about the company's future prospects.On September 12, 2025, a 15-minute chart analysis of TGTX revealed a narrowing of Bollinger Bands, indicating a reduction in the magnitude of stock price fluctuations. Additionally, a KDJ Death Cross is projected to occur on September 18, 2025, at 12:00, which signals a shift in momentum towards the downside, potentially leading to further decreases in stock price [1].
Despite these technical signals, analysts at B. Riley Securities maintain a Buy rating for TGTX, raising the price target from $53.00 to $55.00, reflecting a 3.77% increase. The analyst responsible for this update, Mayank Mamtani, attributes the increase to recent market evaluations and strategic company developments [1].
The consensus among Wall Street analysts is also favorable, with an average target price of $42.00 and an average brokerage recommendation of "Outperform". GuruFocus estimates a GF Value for TGTX of $89.71, suggesting a potential upside of 177.48% from the current price of $32.33 [1].
However, the projected KDJ Death Cross and Bollinger Bands narrowing indicate a cautious approach for investors. While the company's pipeline and recent FDA approval for BRIUMVI for the treatment of relapsing forms of multiple sclerosis (RMS) are positive developments, the technical indicators suggest a potential downward trend in the short term.
Investors should closely monitor TGTX's stock performance and consider the implications of the upcoming KDJ Death Cross on September 18, 2025, while also keeping an eye on the company's broader strategic developments and market evaluations.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet